Two large randomized trials have advanced our knowledge of myeloma care. The first study reported that autologous stem-cell transplantation remains the frontline therapy for transplant-eligible patients with multiple myeloma in the current era of novel agents. Together, this study and the second large trial in transplant-ineligible patients demonstrate the value of maintenance treatment with continuous lenalidomide.
- Gareth J. Morgan
- Frits van Rhee
